Abstract
PurposeTo evaluate the quality of radiomics studies on stroke using a radiomics quality score (RQS), Minimum Information for Medial AI reporting (MINIMAR) and Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) to promote clinical application. MethodsPubMed MEDLINE and Embase were searched to identify radiomics studies on stroke. Of 464 articles, 52 relevant original research articles were included. The RQS, MINIMAR and TRIPOD were scored to evaluate the quality of the studies by neuroradiologists. ResultsOnly four studies (7.7 %) performed external validation. The mean RQS was 3.2 of 36 (8.9 %), and the basic adherence rate was 24.9 %. The adherence rate was low for conducting phantom study (1.9 %), stating comparison to ‘gold standard’ (1.9 %), offering potential clinical utility (13.5 %) and performing cost-effectiveness analysis (1.9 %). None of the studies performed a test–retest, stated biologic correlation, conducted prospective studies, or opened codes and data to the public, resulting in low RQS. The total MINIMAR adherence rate was 47.4 %. The overall adherence rate for TRIPOD was 54.6 %, with low scores for reporting the title (2.0 %), key elements of the study setting (6.1 %), and explaining the sample size (2.0 %). ConclusionsThe overall radiomics reporting quality and reporting of published radiomics studies on stoke was suboptimal. More thorough validation and open data are needed to increase clinical applicability of radiomics studies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.